News Business Sports Entertainment Life Obituaries Opinion
Jobs Homes Cars Classifieds Shopping
Local Bloggers Cheap Tech Eco-Confessions Faceoff Furst Draft Heard on the Street Med City Movie Guy Pulse on Health Political Party

Search PB Blogs

Loading

Categories

16 posts categorized "venture capital"

April 16, 2015

Cardio3 changes name to better fit new focus

The Mayo Clinic-linked firm Cardio3 Biosciences, which is building a manufacturing facility in downtown Rochester, has abruptly decided to change its name to better fit its widening focus in the growing area of cell-based therapies.

Cardiobioscience_jpegThe Belgium-based biotech firm announced Wednesday that it changed its name to Celyad. It started using the new name immediately, though shareholders will not vote on the change until its annual meeting May 5.

This sudden move comes as the company is preparing for an initial public offering on the U.S. stock exchange. Celyad has not released a date for the IPO.

CEO Dr. Christian Homsy was quoted in a company statement saying this new name fits with the firm's new direction following its recent $10 million acquisition of Celdara Medical's oncology division, OnCyte. That signals an expansion beyond its stem-cell-based cardiac regeneration therapy into immuno-oncology. The regenerative stem cell therapy is based on research done by Dr. Andre Terzic and Dr. Atta Behfar, licensed from the Mayo Cli6a00d83451cc8269e201a511d8e824970c-250winic.

“We believe that the name change better aligns our identity with our core activities and overall unified objective of identifying and translating innovative cell-based therapies into therapeutics, not only in cardiology, but now also in oncology and potentially in other areas in the future,” Homsy stated in the announcement of the new name.

Celyad's U.S. communication staff said Wednesday that no one from the company could publicly comment on the name change, other than through the press release. Celyad spokeswoman Kirsten Thomas, of The Ruth Group, explained the silence was due to the U.S Securities Exchange Commission's imposed "quiet period" on promotional publicity during the buildup to the IPO.

Mayo Clinic and Celyad have collaborated since 2007 on the cardiopoiesis technology that the company uses to repair patients' hearts by re-programming their own stem cells to regenerate cardiac tissue. Mayo Clinic owned 2.69 percent of the company as of March 3. Mayo Clinic also is participating in a Celyad clinical trial.
Celyad
If the stem cell therapy makes it to the market, Celyad will pay Mayo Clinic $1 million a year for four years for research as well a 2 percent royalty on sales for 15 years, the press release says.

5503a0ea8a679.image"We are excited that Celyad is branching out beyond cardiology into areas such as oncology," stated Jim Rogers, the chairman of Mayo Clinic Ventures. "Our hope is that they are building a robust capability to deliver breakthrough therapies in the area of regenerative medicine, which is a significant priority for Mayo as well."

The name change comes before new signs have gone up in the city of Rochester's Minnesota Biobusiness Center. The city signed a lease with Celyad earlier this year for it to develop a prototype manufacturing facility in the 14,963 square feet of space on the fifth floor of the downtown building. The five-year lease calls for Celyad to pay a rent of $18 per square foot, or $22,444.50 per month. The city agreed in the lease to pay for $600,000 in equipment and improvements to the space.

The Minnesota Department of Employment and Economic Development also signed a deal with Celyad on Jan. 12 to receive a Minnesota Job Creation Fund award of $357,000. To collect the money, it must invest $1.5 million in Rochester within a year, plus hire 33 employees within two years.

The ultimate goal of the project is for the city, state and Rochester Area Economic Development Inc. to eventually convince Celyad to build a 100,000-square-foot manufacturing facility with 350 employees in Rochester, according to RAEDI officials.

However, Rochester is not the only city wooing the Belgium company. While the Rochester facility is the company's first official U.S. location, it also has plans to build a U.S. headquarters in Boston.

It seems as though Celyad is at a turning point. The company has worked on developing its cardiac regenerative therapy since 2007. While it has seen many positive results from trials in Europe and research in the United States, it has no products currently on the market.

The company lost $18.1 million in 2014, up from $15.9 million in losses in 2013. While the cardiopoiesis technology developed by Mayo Clinic appears to be promising, the company seems to be embracing the new CAR T-Cell cancer-fighting approach — essentially, a cancer vaccine — that it purchased from Celdara Medical for $10 million earlier this year.

"Our acquisition of the OnCyte CAR T-Cell portfolio in early 2015 heralds the first major step in our strategy to leverage our unique expertise in cell therapies and drug development to expand beyond the cardiac arena to develop breakthrough treatments to change the outcome of disease," stated Homsy last month.

"We are excited to be expanding our product offering into the prominent area of immuno-oncology and anticipate the initiation of the Phase I trial of our lead immuno-oncology candidate, CAR-NKG2D in the first half of 2015 and look forward to sharing details of our progress as we evaluate its clinical potential," Homsy said. "We intend to leverage our cell therapy know-how and infrastructure to quickly progress those assets into later stage clinical trials in 2016, aiming at more than five trials in liquid and solid tumors in the USA and Europe."

Many companies are vying for a spot in the hot CAR T-Cell area to be the one to develop the breakthrough cancer vaccine. The worldwide market for such vaccines was recently estimated to $8.4 billion in 2020.

March 06, 2015

10 years of blogging Rochester

On March 4, 2005, I wrote my first blog post. Kiger's Notebook blogo 2x

It was my sixth year at the Post-Bulletin. I created the "Heard on the Street" column about three years before the blog began. 

More  than 6,200 posts, stacks of columns, mountains of tweets and many gray hairs later, I'm still here writing about business and things vaguely related to businesPhoto on 2015-03-03 at 18.11s in southeastern Minnesota.

It'syou, the readers, who make this career such a fulfilling and entertaining one. Thank you everyone for your feedback, criticism and support over these past 10 years. 

10 years of blogging Rochester

On March 4, 2005, I wrote my first blog post.Kiger's Notebook blogo 2x

It was my siPhoto on 2015-03-03 at 18.11xth year at the Post-Bulletin. I created the "Heard on the Street" column about three years before the blog began. 

More than 6,200 posts, stacks of columns, mountains of tweets and many gray hairs later, I'm still here writing about business and things vaguely related to business in southeastern Minnesota.

It's you, the readers, who make this career such a fulfilling and entertaining one. Thank you everyone for your feedback, criticism and support over these past 10 years.  

June 25, 2014

Mayo Clinic-linked NeoChord gets new leader

An Eden Prairie company that makes a medical device based on Mayo Clinic research named a new leader this week for the first time since it launched in 2007.

NeoheartNeoChord announced that David H. Chung was appointed as president and CEO, "effective immediately." He replaced John Seaberg, who resigned.

“David Chung’s extensive experience in building and managing international sales forces will be invaluable, as we introduce NeoChord’s innovative technology to patients throughout Europe,” said Dr. Michael Fulton, Neochord's chairman of the board.

For the past seven years, the company has been developing a device designed by Mayo Clinic cardiac surgeons Dr. Richard Daly and Dr. Giovanni Speziali. Beside licensing its technology, Mayo Clinic also is invested in an equity position in the firm. Speziali was named as the company's chief medical officer in 2013.

The NeoChord DS1000 device is used to treat a heart condition called mitral regurgitation. Mitral regurgitation means the valve or leaflet that controls the flow of blood from the left atrium to the left ventricle is not working properly.

Portfolio-neochord-260x138Treatment typically consists of “cracking the chest,” stopping the heart and doing surgery. NeoChord's approach is much less invasive and can be done on a beating heart. A tool is inserted between the ribs and into the heart. Then it is used to attach a chord to the faulty valve leaflet, which is tethered to the heart.

The former CEO Seaburg described the process as “a very elegant treatment."

A Transapical Artificial Chordae Tendinae (TACT) trial is underway to evaluate the NeoChord DS1000. The system now is being used to treat patients in 18 hospitals across eight countries in Europe. More than 120 patients have been treated. It is not yet cleared for commercial use in the U.S.

The market for less invasive techniques for mitral valve repair has been estimated at more than $2 billion. There are 50,000 surgeries done in the U.S. each year. An estimated 2 million patients are treated due to the risks of surgery.

Since it formed in 2007, NeoChord's lifeblood has been venture capital funding. By 2008, it had raised $3 million. It raised another $5.1 million in 2011 to finance the European clinical trial. In March 2013, it raised $3 million through the sale of its series B-2 preferred stock.

December 05, 2013

Breast cancer scanner maker, once linked to Mayo Clinic, sold to Mexican company

Qg3q4q112233Here's a potentially interesting nugget of news about San Diego-based Naviscan Inc., which was at one pointed linked with Mayo Clinic through intellectual property licenses as well as direct investment by Mayo Medical Ventures.

"… Certain Naviscan Inc. assets including intellectual property and the Naviscan Trademark" have been aquired by a Mexican medical scanner company called Compañía Mexicana de Radiología or CMR.

Not sure what that means exactly, but my guess is that CMR is now behind the steering wheel at Naviscan.

Now I don't know if Mayo Clinic still has any links with Naviscan, but it certainly did at one time. I've got calls into Mayo and Naviscan to check on that.

I wrote the Mayo Clinic-Naviscan relationship back in 2005 through 2007 or so. Sheesh, I've been doing this for a long time.

From back in November 2005:

Naviscan “entered into an agreement with Mayo Foundation for Medical Education and Research (Mayo Clinic) to clinically validate and commercialize a dynamic patented molecular imaging agent for use with Positron Emission Tomography (PET) and other imaging modalities. … Mayo Clinic has licensed the vitamin B-12 molecular imaging agent technology invented by Dr. Douglas A.Collins to Naviscan PET Systems, Inc and will receive royalties from this license. Researchers at the Mayo Clinic have published studies that cancers have high uptake of radioactive B-12, especially in breast tumors."

    --------------------
"The combination of the Mayo Clinic’s patented Vitamin B-12 molecular imaging agent and Naviscan’s high-resolution PET scanner holds great promise for the future in terms of early detection of breast cancers,” said Paul Grayson, newly-appointed CEO of Naviscan PET Systems, Inc. and a Managing Director of Sanderling Ventures. “We sought out Naviscan’s technology to strategically invest in this important imaging technology platform.” Naviscan is planning clinical trial work with Mayo Clinic and other luminary sites in the U.S. to prove the value of the PEM Flex in breast cancer patients, as well as for evaluating PEM’s role with high-risk patients.”

----

From the same date in 2005:

“Naviscan PET Systems has raised a $6.5 million in Series B funding for its high resolution positron emission tomography (PET) products. The firm said that it raised the round from Sanderling Ventures, with participation from Mayo Medical Ventures."

FYI, Sanderling Ventures now leases a space in the Mayo Clinic Business Accelerator.

November 11, 2013

Mayo Clinic, U of M startup ready for software rollout

Rochester's Evidentia Health got some press last week about its impending rollout at Fairview Health Systems.

Evidentia Health was one of the first tenants of Mayo Clinic Business Accelerator when it opened early this year.

Its billed as a health care IT company with licensed expe02272013mayoaccelerator1rtise and medical content from both Mayo Clinic and the University of Minnesota

It was co-founded by Mayo Clinic's Dr. Jeremy Friese in early 2012.Friese, an interventional radiologist, is the medical director for new ventures and business development in the Mayo Clinic's Center for Individualized Medicine.

Evidentia was profiled on Wednesday by TechdotMN, a non-profit business media group. Here's some from that piece by Yael Grauer:

As new provisions from the Affordable Healthcare Act take effect, Minnesota startup Evidentia Health is poised to help patients better understand their electronic health records (EHRs) while helping physicians meet criteria for “meaningful use” of EHR technology to improve patient care.

To receive EHR incentive pay under Medicare and Medicaid EHR Incentive Programs, healthcare providers must show they are meaningfully using EHRs by meeting various objectives.  Patients are required to be able to access their medical information within three days of when it’s created, and in 2014, this will be within one day.

The problem is that viewing EHR material and doing research online can be confusing to patients. They can jump to the wrong conclusions, worry unnecessarily and often have questions for their care team that may not be applicable.

Evidentia provides reports to both patients and physicians. The reports for patients include the most important sources of information, as well as secondary information for those interested in even more. In addition to the material in patient reports, physicians also receive recent medical research for evidence-based medicine studies.

----

Founded in October 2012, Evidentia is funded by Mayo Clinic Ventures and the University of Minnesota. A pilot program is taking place at the Family Practice Internal Medicine groups in Rochester, and Evidentia is prepared to deploy within Fairview at University Hospital.

As new provisions from the Affordable Healthcare Act take effect, Minnesota startup Evidentia Health is poised to help patients better understand their electronic health records (EHRs) while helping physicians meet criteria for “meaningful use” of EHR technology to improve patient care.

To receive EHR incentive pay under Medicare and Medicaid EHR Incentive Programs, healthcare providers must show they are meaningfully using EHRs by meeting various objectives.  Patients are required to be able to access their medical information within three days of when it’s created, and in 2014, this will be within one day.

The problem is that viewing EHR material and doing research online can be confusing to patients. They can jump to the wrong conclusions, worry unnecessarily and often have questions for their care team that may not be applicable.

Evidentia provides reports to both patients and physicians. The reports for patients include the most important sources of information, as well as secondary information for those interested in even more. In addition to the material in patient reports, physicians also receive recent medical research for evidence-based medicine studies.

“Evidentia brings together all of the information that you need to know and get it in your hands in a way that’s both credible and trustworthy, has been reviewed by physicians, and is applicable to your situation,” says CTO Brent Backhaus.

When patients access their electronic medical records, they’ve often confused about certain key phrases or conditions. Evidentia looks at the text of the reports, highlights key phrases, and presents individualized information to the patient. The information selected is both algorithmically selected and reviewed by a physician.

“We pick information to present to both to the patient and the physician that make the most sense for them to see at that point in time about their specific condition,” Backhaus says.

In addition to Backhaus, who was the founding CTO of Virtual Radiologic, Evidentia’s team includes CEO Jeremy Friese, a Harvard MBA and Associate Chair of Radiology at Mayo Clinic, and chief product officer Dan Steinberger, a U of M physician and technology leader, and founder of ProVation Medical (which had a $100m exit in 2006).

Founded in October 2012, Evidentia is funded by Mayo Clinic Ventures and the University of Minnesota. A pilot program is taking place at the Family Practice Internal Medicine groups in Rochester, and Evidentia is prepared to deploy within Fairview at University Hospital.

- See more at: http://tech.mn/news/2013/11/06/evidentia-health-mayo-clinic-ventures/#sthash.tL8tSBOX.dpuf
Yael Grauer
Yael Grauer
Yael Grauer
Yael Grauer

As new provisions from the Affordable Healthcare Act take effect, Minnesota startup Evidentia Health is poised to help patients better understand their electronic health records (EHRs) while helping physicians meet criteria for “meaningful use” of EHR technology to improve patient care.

To receive EHR incentive pay under Medicare and Medicaid EHR Incentive Programs, healthcare providers must show they are meaningfully using EHRs by meeting various objectives.  Patients are required to be able to access their medical information within three days of when it’s created, and in 2014, this will be within one day.

The problem is that viewing EHR material and doing research online can be confusing to patients. They can jump to the wrong conclusions, worry unnecessarily and often have questions for their care team that may not be applicable.

Evidentia provides reports to both patients and physicians. The reports for patients include the most important sources of information, as well as secondary information for those interested in even more. In addition to the material in patient reports, physicians also receive recent medical research for evidence-based medicine studies.

“Evidentia brings together all of the information that you need to know and get it in your hands in a way that’s both credible and trustworthy, has been reviewed by physicians, and is applicable to your situation,” says CTO Brent Backhaus.

When patients access their electronic medical records, they’ve often confused about certain key phrases or conditions. Evidentia looks at the text of the reports, highlights key phrases, and presents individualized information to the patient. The information selected is both algorithmically selected and reviewed by a physician.

“We pick information to present to both to the patient and the physician that make the most sense for them to see at that point in time about their specific condition,” Backhaus says.

In addition to Backhaus, who was the founding CTO of Virtual Radiologic, Evidentia’s team includes CEO Jeremy Friese, a Harvard MBA and Associate Chair of Radiology at Mayo Clinic, and chief product officer Dan Steinberger, a U of M physician and technology leader, and founder of ProVation Medical (which had a $100m exit in 2006).

Founded in October 2012, Evidentia is funded by Mayo Clinic Ventures and the University of Minnesota. A pilot program is taking place at the Family Practice Internal Medicine groups in Rochester, and Evidentia is prepared to deploy within Fairview at University Hospital.

- See more at: http://tech.mn/news/2013/11/06/evidentia-health-mayo-clinic-ventures/#sthash.tL8tSBOX.dpufis it will roll out its technology this year.

March 01, 2013

Mayo Clinic Biz Accelerator already speeding along

Here's some from my 2nd Mayo Clinic Business Accelerator story of the week. I'll have more in seperate post soon.
The just-opened Mayo Clinic Business Accelerator is already bursting at the seams with companies, including some local start-ups that are ready to aim high.

051509biobusinesscenteratnight"We want to be the Amgen (the largest biotechnology company in the world) of Rochester," says Dr. John Burnett Jr., who with Dr. Horng Chen founded Zumbro Discovery just a few weeks ago.

The pair develop peptides to help treat medical conditions and two of their previous creations were licensed by out-of-state companies.

"We really had the desire to set something up here," says Chen. And as the inventors, they believe they will be able to better direct the course of the product as well as do it faster.

Their first patented peptide is designed to treat a condition known as Resistant Hypertension. It is generally defined as high blood pressure that standard treatments can't lower. About 10 to 20 percent of people diagnosed with hypertension are believed to be resistant.
It can lead to heart failure, myocardial infarction, stroke as well as kidney failure.

The Federal Drug Administration has already given the doctors the greenlight to begin testing on patients with Resistant Hypertension and they hope to do that by the end of the year.

"Being in the Accelerator is great for a young, virtual company like us. It gives a chance to interact with venture capitalists and network with other businesses," says Burnett. "And it is just a short walk from our lab."

The Accelerator offices in the Minnesota BioBusiness Center were packed this morning as crowds of Mayo Clinic administrators, city officials and community leaders packed into the just-completed space to christian is open for business.

It's "business" is to speed up local business development and ultimately create new jobs.

“The Accelerator is an example of the strength of a strong partnership between Mayo Clinic and the community to make it easier and more affordable for companies to start and locate in Rochester,” says Mayo Clinic CEO Dr. John Noseworthy.

A collaboration between Mayo Clinic, the City of Rochester and Rochester Area Economic Development Inc., the Accelerator is starting out with a full boat of tenants that include biotech businesses, medical device makers, software start-ups, venture capitalists and health care consultants.

Funded by $100,000 from Mayo Clinic and $100,000 from local sales tax money, the 2,500-square-foot cluster of offices is located on the second floor of the city-owned Minnesota BioBusiness Center. RAEDI is handling the management and leasing of the space.

“We hope to provide a nurturing space for new company formation in Rochester,” says Jim Rogers of Mayo Clinic Ventures.

February 27, 2013

A window on Mayo Clinic's business accelerator plans

It is getting close to the big reveal of the Mayo Clinic Business Accelerator in the City of Rochester's Minnesota BioBusiness Center.

02272013mayoaccelerator1The plan, as I understand it, is to announce the new tenants - possibly eight - in the 2,500-square-foot center at RAEDI's annual meeting on Thursday. Remember this new twist on a business incubator is designed to house early biotech start-ups as well as venture capitalists. The tenant names have been kept hidden from anyone outside of Mayo Clinic and the usual insider crowd of public figures.

And yet this morning, a couple of venture capitalist firms' names are as clear as glass as being part of this private/public project.

Sanderling Ventures and Versant Ventures are up on the window, along with Mayo Clinic Ventures, the City of Rochester and RAEDI.

The California-based firm has a lot of experience working with Mayo Clinic and Mayo-related companies, like Torax and Naviscan.

02272013mayoaccelerator2I don't know as much as about Versant Ventures, but it is also based in California. However, it also has an office in Minneapolis.

Here's some background on the accelerator:

Mayo Clinic is giving $100,000 to turn the unused space, which is owned by the city, into offices. RAEDI will handle the management and leasing of the space.

HGA, which was the architect firm for the building, handled designs for this space. Lots of glass walls, I hear. Rents are expected to range from $13 to $15 per square foot.

January 23, 2012

Mayo Clinic-linked med device firm close to FDA OK

Here's a little from an interestng piece by Lindsay Patton on Dailyrx.com about Torax Medical's anti-acid reflux device.

Mayo Clinic helped launch Torax in 2003 and Mayo Medical Ventures has invested in the company in the past.

John Deedrick, a Rochester venture capitalist who previously worked with Mayo Clinic, is also on Torax's board of directors.

-----------

A FDA panel has given unanimous support to LINX, an implantable device to treat chronic and severe acid reflux. That means LINX is one step closer to being available for US patients.

TORAX_twitter_picThe LINX Reflux Management System is a flexible ring of titanium magnetic beads. It's implanted on the lower end of the esophagus to prevent stomach acid and food from rising.

The magnetic attraction between the beads work to resist the gastric pressure that causes acid reflux. But when people are eating, it allows food and liquids to pass into the stomach normally.

LINX is produced by Torax Medical, a medical device company based in Minnesota. The device has already been on the market in some European countries for two years.

LINX-588x330------

LINX is not recommended for patients who need MRI scans, due to the magnetic nature of the beads.

Torax plans a follow-up study of 200 patients to test LINX's long-term safety and effectiveness.

September 22, 2011

The Belgians are coming - Mayo Clinic-linked firm opening Roch. subsidary

Here's some from a piece I whipped up today about a Belgium biotech company, Cardio3, opening a U.S. office in the US. I've have been following these guys for years.

They are a pretty interesting firm.

The whole story is in today's print edition, including more about the potential of what this could mean for Rochester.

---------------

After years of talks, a Belgium company that uses stem cells to repair the heart is coming to Rochester in what local officials hope will be the start of a cluster of regenerative medicine firms here.
6a00d83451cc8269e2014e87420421970d-250wi
Cardio3 BioSciences, which is based on Mayo Clinic-licensed research by Dr. Atta Behfar and Dr. Andre Terzic, uses a patient's own stem cells from bone marrow to repair heart damage.

Clinical trials with patients in Europe have shown positive results. Now the company is establishing a subsidiary in Rochester to begin trials in the United States.

"What is unique about this is it's Mayo intellectual property that they are commercializing, which they took to it Belgium … and now it has come full circle back to Rochester," said Rochester Area Economic Development Inc. President Gary Smith. "That is a big thing … a very big thing."